Mark Talamonti to Dermatologic Agents
This is a "connection" page, showing publications Mark Talamonti has written about Dermatologic Agents.
Connection Strength
2.487
-
Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience. Expert Opin Biol Ther. 2020 01; 20(1):95-104.
Score: 0.669
-
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. J Eur Acad Dermatol Venereol. 2018 Oct; 32(10):1737-1744.
Score: 0.607
-
Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients. Br J Dermatol. 2017 Aug; 177(2):489-496.
Score: 0.568
-
Patients with moderate to severe plaque psoriasis: one year after the European Medicines Agency recommendation of efalizumab suspension. Dermatology. 2011; 222(3):250-5.
Score: 0.370
-
Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts. J Eur Acad Dermatol Venereol. 2020 Jan; 34(1):112-118.
Score: 0.165
-
The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab. Dermatology. 2010; 221 Suppl 1:43-7.
Score: 0.088
-
Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers. Dermatology. 2009; 219(1):48-53.
Score: 0.020